Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.39 |
| ▸ | TXK | P42681 | 6/20 | 0.37 |
| ▸ | ITK | Q08881 | 6/20 | 0.37 |
| ▸ | TEC | P42680 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TET3 | O43151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.36 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.36 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21303477 | 1.00 | BTK (0.39) | BTKTXKITKTECALDH1A1 | |
| SCHEMBL16375283 | 0.92 | KMT2A (0.40) | BTKCYP1A2CYP2C9TET3KMT2A | |
| SCHEMBL16375281 | 0.91 | CYP2D6 (0.41) | BTKALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15474352 | 0.89 | BTK (0.41) | BTK | |
| SCHEMBL26294933 | 0.83 | BTK (0.36) | BTKTET3KMT2AFBXL19CXXC5 | |
| SCHEMBL16375282 | 0.83 | JAK3 (0.35) | BTKTET3KMT2AFBXL19CXXC5 | |
| SCHEMBL19892203 | 0.82 | BTK (0.41) | BTKTXKITKTECTET3 | |
| SCHEMBL15474354 | 0.82 | BTK (0.41) | BTKTXKITKTECTET3 | |
| SCHEMBL18256186 | 0.82 | CYP3A4 (0.43) | ALDH1A1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15474363 | 0.78 | BTK (0.39) | BTKTXKITKTECTET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019040512-A1 | BENZIMIDAZOLE COMPOUNDS AS KINASE INHIBITORS | GB005, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-9828364-B2 | Pyrazole compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| US-9828364-B2 | Pyrazole compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-28 | — | — | US | disclosed |
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| US-20160031872-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-02-04 | — | — | US | disclosed |
| US-8940893-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8940893-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-27 | — | — | US | disclosed |
| US-20140275014-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
| US-20140275014-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275014-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885TXK 211/4885ITK 305/4885 |
| US-20160340339-A1 | PYRAZOLE COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885TXK 150/4885ITK 172/4885 |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | BTK 1/4885TXK 161/4885ITK 392/4885 |
| US-20160031872-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | BTK 1/4885TXK 161/4885ITK 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.